68. O.C. Farokhzad, S. Jon, A. Khademhosseini, TNT Tran, DA LaVan, R. Langer,
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Cancer Res. 64(21), 7668–7672 (2004)
69. P.E. Saw, S. Kim, Lee I-h, J. Park, M. Yu, J. Lee et al., Aptide-conjugated liposome
targeting tumor-associated fibronectin for glioma therapy. J. Mater. Chem. B Mater. Biol.
Med. 1(37), 4723–4726 (2013)
70. V.J. Ruigrok, M. Levisson, M.H. Eppink, H. Smidt, J. van der Oost, Alternative affinity
tools: more attractive than antibodies? Biochem. J. 436(1), 1–13 (2011)
71. A.M. Scott, J.D. Wolchok, L.J. Old, Antibody therapy of cancer. Nat. Rev. Cancer 12(4),
278–287 (2012)
72. T.E. Witzig, L.I. Gordon, F. Cabanillas, M.S. Czuczman, C. Emmanouilides, R. Joyce et al.,
Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,
follicular, or transformed b-cell non-hodgkin’s lymphoma. J. Clin. Oncol. 20(10), 2453–
2463 (2002)
73. R.L. Wahl, Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J. Nucl. Med. 46
(Suppl 1), 128S–140S (2005)
74. H. Hong, Y. Zhang, G.W. Severin, Y. Yang, J.W. Engle, G. Niu et al., Multimodality
imaging of breast cancer experimental lung metastasis with bioluminescence and a
monoclonal antibody dual-labeled with
89
Zr and IRdye 800cw. Mol. Pharm. 9(8), 2339–
2349 (2012)
75. R. Rezaeipoor, R. John, S.G. Adie, E.J. Chaney, M. Marjanovic, A.L. Oldenburg et al.,
Fc-directed antibody conjugation of magnetic nanoparticles for enhanced molecular
targeting. J. Innov. Opt. Health Sci. 2(4), 387–396 (2009)
76. S. Kumar, J. Aaron, K. Sokolov, Directional conjugation of antibodies to nanoparticles for
synthesis of multiplexed optical contrast agents with both delivery and targeting moieties.
Nat. Protoc. 3(2), 314–320 (2008)
77. M.M. Cardoso, I.N. Peca, A.C. Roque, Antibody-conjugated nanoparticles for therapeutic
applications. Curr. Med. Chem. 19(19), 3103–3127 (2012)
78. S. Jeong, J.Y. Park, M.G. Cha, H. Chang, Y.I. Kim, H.M. Kim et al., Highly robust and
optimized conjugation of antibodies to nanoparticles using quantitatively validated
protocols. Nanoscale 9(7), 2548–2555 (2017)
79. H. Wang, Y.L. Liu, Y.H. Yang, T. Deng, G.L. Shen, R.Q. Yu, A protein A-based
orientation-controlled immobilization strategy for antibodies using nanometer-sized gold
particles and plasma-polymerized film. Anal. Biochem. 324(2), 219–226 (2004)
80. S. Mazzucchelli, M. Colombo, C. De Palma, A. Salvade, P. Verderio, M.D. Coghi et al.,
Single-domain protein a-engineered magnetic nanoparticles: toward a universal strategy to
site-specific labeling of antibodies for targeted detection of tumor cells. ACS Nano 4(10),
5693–5702 (2010)
81. A. Makaraviciute, A. Ramanaviciene, Site-directed antibody immobilization techniques for
immunosensors. Biosens. Bioelectron. 50, 460–471 (2013)
82. M. Salehi, L. Schneider, P. Strobel, A. Marx, J. Packeisen, S. Schlucker, Two-color SERS
microscopy for protein co-localization in prostate tissue with primary antibody-protein A/
G-gold nanocluster conjugates. Nanoscale 6(4), 2361–2367 (2014)
83. B. Dubertret, P. Skourides, D.J. Norris, V. Noireaux, A.H. Brivanlou, A. Libchaber, In vivo
imaging of quantum dots encapsulated in phospholipid micelles. Science 298(5599), 1759–
1762 (2002)
84. H. Fan, K. Yang, D.M. Boye, T. Sigmon, K.J. Malloy, H. Xu et al., Self-assembly of
ordered, robust, three-dimensional gold nanocrystal/silica arrays. Science 304(5670), 567–
571 (2004)
85. H. Fan, E.W. Leve, C. Scullin, J. Gabaldon, D. Tallant, S. Bunge et al., Surfactant-assisted
synthesis of water-soluble and biocompatible semiconductor quantum dot micelles. Nano
Lett. 5(4), 645–648 (2005)
226
D. S. Lee et al.
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Cancer Res. 64(21), 7668–7672 (2004)
69. P.E. Saw, S. Kim, Lee I-h, J. Park, M. Yu, J. Lee et al., Aptide-conjugated liposome
targeting tumor-associated fibronectin for glioma therapy. J. Mater. Chem. B Mater. Biol.
Med. 1(37), 4723–4726 (2013)
70. V.J. Ruigrok, M. Levisson, M.H. Eppink, H. Smidt, J. van der Oost, Alternative affinity
tools: more attractive than antibodies? Biochem. J. 436(1), 1–13 (2011)
71. A.M. Scott, J.D. Wolchok, L.J. Old, Antibody therapy of cancer. Nat. Rev. Cancer 12(4),
278–287 (2012)
72. T.E. Witzig, L.I. Gordon, F. Cabanillas, M.S. Czuczman, C. Emmanouilides, R. Joyce et al.,
Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,
follicular, or transformed b-cell non-hodgkin’s lymphoma. J. Clin. Oncol. 20(10), 2453–
2463 (2002)
73. R.L. Wahl, Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J. Nucl. Med. 46
(Suppl 1), 128S–140S (2005)
74. H. Hong, Y. Zhang, G.W. Severin, Y. Yang, J.W. Engle, G. Niu et al., Multimodality
imaging of breast cancer experimental lung metastasis with bioluminescence and a
monoclonal antibody dual-labeled with
89
Zr and IRdye 800cw. Mol. Pharm. 9(8), 2339–
2349 (2012)
75. R. Rezaeipoor, R. John, S.G. Adie, E.J. Chaney, M. Marjanovic, A.L. Oldenburg et al.,
Fc-directed antibody conjugation of magnetic nanoparticles for enhanced molecular
targeting. J. Innov. Opt. Health Sci. 2(4), 387–396 (2009)
76. S. Kumar, J. Aaron, K. Sokolov, Directional conjugation of antibodies to nanoparticles for
synthesis of multiplexed optical contrast agents with both delivery and targeting moieties.
Nat. Protoc. 3(2), 314–320 (2008)
77. M.M. Cardoso, I.N. Peca, A.C. Roque, Antibody-conjugated nanoparticles for therapeutic
applications. Curr. Med. Chem. 19(19), 3103–3127 (2012)
78. S. Jeong, J.Y. Park, M.G. Cha, H. Chang, Y.I. Kim, H.M. Kim et al., Highly robust and
optimized conjugation of antibodies to nanoparticles using quantitatively validated
protocols. Nanoscale 9(7), 2548–2555 (2017)
79. H. Wang, Y.L. Liu, Y.H. Yang, T. Deng, G.L. Shen, R.Q. Yu, A protein A-based
orientation-controlled immobilization strategy for antibodies using nanometer-sized gold
particles and plasma-polymerized film. Anal. Biochem. 324(2), 219–226 (2004)
80. S. Mazzucchelli, M. Colombo, C. De Palma, A. Salvade, P. Verderio, M.D. Coghi et al.,
Single-domain protein a-engineered magnetic nanoparticles: toward a universal strategy to
site-specific labeling of antibodies for targeted detection of tumor cells. ACS Nano 4(10),
5693–5702 (2010)
81. A. Makaraviciute, A. Ramanaviciene, Site-directed antibody immobilization techniques for
immunosensors. Biosens. Bioelectron. 50, 460–471 (2013)
82. M. Salehi, L. Schneider, P. Strobel, A. Marx, J. Packeisen, S. Schlucker, Two-color SERS
microscopy for protein co-localization in prostate tissue with primary antibody-protein A/
G-gold nanocluster conjugates. Nanoscale 6(4), 2361–2367 (2014)
83. B. Dubertret, P. Skourides, D.J. Norris, V. Noireaux, A.H. Brivanlou, A. Libchaber, In vivo
imaging of quantum dots encapsulated in phospholipid micelles. Science 298(5599), 1759–
1762 (2002)
84. H. Fan, K. Yang, D.M. Boye, T. Sigmon, K.J. Malloy, H. Xu et al., Self-assembly of
ordered, robust, three-dimensional gold nanocrystal/silica arrays. Science 304(5670), 567–
571 (2004)
85. H. Fan, E.W. Leve, C. Scullin, J. Gabaldon, D. Tallant, S. Bunge et al., Surfactant-assisted
synthesis of water-soluble and biocompatible semiconductor quantum dot micelles. Nano
Lett. 5(4), 645–648 (2005)
226
D. S. Lee et al.